Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Core Insights - Lifecore Biomedical has signed a CDMO master services agreement with a large global pharmaceutical customer for the development and tech transfer of an injectable pharmaceutical product, aiming to become the commercial supplier of choice after regulatory requirements are met [1][2] - This agreement marks the second partnership with a multinational pharmaceutical company within three months, positioning the new partner to potentially be among Lifecore's top five commercial customers based on current revenues [2] - The CEO of Lifecore expressed excitement about the momentum generated by the business development team, highlighting the company's competitive differentiation in quality, technical expertise, and reliability for sterile injectables [3] Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across various therapeutic categories [4]